TD Asset Management Inc. Reduces Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

TD Asset Management Inc. lowered its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 463,961 shares of the company’s stock after selling 39,113 shares during the period. TD Asset Management Inc. owned 1.49% of Medpace worth $154,142,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MEDP. Centaurus Financial Inc. boosted its holdings in shares of Medpace by 2.0% during the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after purchasing an additional 29 shares during the last quarter. Lindbrook Capital LLC boosted its stake in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after buying an additional 29 shares during the last quarter. HBK Sorce Advisory LLC grew its holdings in Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after buying an additional 29 shares in the last quarter. Assetmark Inc. increased its stake in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after acquiring an additional 29 shares during the last quarter. Finally, Proficio Capital Partners LLC increased its stake in shares of Medpace by 4.1% in the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock worth $243,000 after acquiring an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of analyst reports. Robert W. Baird upped their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Leerink Partnrs raised shares of Medpace to a “hold” rating in a research note on Monday. Finally, Leerink Partners initiated coverage on shares of Medpace in a research report on Monday. They set a “market perform” rating and a $330.00 price target on the stock. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $376.30.

Medpace Stock Performance

Shares of MEDP stock opened at $324.51 on Wednesday. The firm has a market cap of $9.89 billion, a P/E ratio of 25.69, a P/E/G ratio of 3.81 and a beta of 1.47. The firm’s 50 day moving average price is $337.16 and its 200-day moving average price is $339.57. Medpace Holdings, Inc. has a one year low of $302.01 and a one year high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.